Elon developed incontinence drug
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Reporting by The New York Times, amplified by outlets including Rolling Stone, People, TechCrunch and others, says Elon Musk increased use of ketamine and other drugs during the 2024 campaign to the point that it “was affecting his bladder,” a known effect of chronic ketamine use [1][2][3]. The Times account and follow‑ups say the drug use included ketamine, psychedelics, ecstasy and prescription stimulants and provoked internal concern at companies and public pushback; the NYT has defended its reporting amid denials from Musk [1][4][5].
1. What the reporting actually says — a compact reconstruction
The New York Times’ reporting, which multiple outlets summarize, describes a period during the 2024 campaign when Musk’s drug use reportedly intensified — “sometimes daily” ketamine use mixed with other substances — and that he privately complained the ketamine was harming his bladder function, a complication clinicians associate with chronic, heavy ketamine use [1][2][6]. TechCrunch and People cite the Times as saying Musk’s drug use included ketamine, hallucinogenic mushrooms, ecstasy and the prescription stimulant Adderall and that company board members were reportedly worried [4][3].
2. Medical context: ketamine and bladder damage
Independent medical literature and reporting cited in the coverage note a recognized syndrome from recreational ketamine — often called “ketamine bladder syndrome” — that can include bladder pain, frequency, incontinence and other severe urologic damage; outlets referencing that literature use it to explain why chronic ketamine use can affect bladder function [6]. Rolling Stone and Futurism explicitly link chronic ketamine patterns described in the Times to known bladder risks [2][6].
3. Sources, denials and journalistic pushback
The NYT piece rests on interviews and documentation; it prompted public denials from Musk — who has told reporters the paper was wrong and said he did not use drugs — and the Times publicly defended its reporting [1][5]. Coverage in Deadline emphasizes that the Times stood by its account after attacks and denials [5].
4. How other outlets framed the same material
Rolling Stone, People, TechCrunch and the Times align on the core claims: increased drug use during the campaign and bladder complaints attributed to ketamine [2][3][4][1]. Futurism expanded the piece with explicit reference to the 2012 medical study describing ketamine bladder syndrome and noted clinicians’ recent observations of rising ketamine‑related bladder problems in younger patients [6].
5. What this reporting does not prove — limitations in the public record
Available sources do not include medical records, a direct statement from treating clinicians, toxicology reports, or an on‑the‑record medical confirmation tying Musk’s personal symptoms to ketamine; the public record relies on reporting and anonymous sources summarized by the Times and republished by other outlets [1][4]. None of the provided sources furnishes primary medical documentation or a direct quote from Musk’s clinicians; Deadline and the Times note defenses and denials but the underlying clinical proof is not in the available reporting [5][1].
6. Competing narratives and possible agendas
The story sits at an intersection of political drama (Musk’s visible role in the 2024 campaign), corporate governance (board concerns at Tesla/SpaceX per reporting), and celebrity scrutiny; outlets sympathetic to the Times emphasize public‑interest reporting about a powerful CEO’s fitness, while Musk’s denials and attacks on the paper align with a strategy to discredit adverse coverage. Deadline’s coverage underscores the newsroom’s defense, suggesting the Times anticipated politicized pushback [5][1][4].
7. What readers should take away
The best, supported summary: multiple reputable outlets report the NYT’s claim that Musk’s ketamine use increased during the 2024 campaign and that he complained of bladder effects consistent with known ketamine risks; the NYT stands by its reporting while Musk denies the allegations [1][2][5]. Medical literature cited by secondary outlets links chronic ketamine use to bladder damage, but publicly available reporting does not include independent medical records proving causation in this individual case [6][1].
If you want, I can pull exact quotations from The New York Times article and the Times’ public defense coverage, or assemble the chronology of when outlets published their summaries.